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Summary The purpose of the present study was to explore the therapeutic potential of serial administration of
shedding- inducing endotoxin in a mouse tumour bladder model. The studies were conducted with two variants
derived from the MBT-2 tumour namely, T5 and T50, the latter being far more aggressive than the former. It
was found that T5 tumours responded to intravesical lipopolysaccharides (LPS) instillation by a considerable
reduction in their pace of growth (P<0.0001) when treatment was initiated 3 days after tumour implantation,
but not when started after 7 days. The T50 variant did not respond to LPS when treated 3 days after
implantation, but a considerable reduction in rate of growth occurred when treatment was started after 1-2
days. Shedding induced by intravesically instilled LPS was found to retard considerably the progression rate of
experimental bladder tumour.
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Carcinoma of the bladder is the second most common
urological neoplasm, accounting for approximately 5% of all
new malignancies and 1.9% of all cancer deaths in the United
States (Silverberg et al., 1990). Papillary superficial transi-
tional cell carcinoma is the most common type representing
75% of initial tumour events; of these, approximately 70%
involve only the mucosa (Ta, Tis), while 30% invade the
lamina propria (TI).
If treated by endoscopic resection alone, about 50% to
70% of these tumours will recur locally and usually display
the same grade and stage (Torti and Lum, 1984; Rubben et
al., 1988); hence, many of the patients are candidates for
intravesical therapy. Response to the available intravesical
agents ranges between 30% and 70% (depending on the drug
used), and all of them are associated with serious side-effects
(Herr et al., 1987; Soloway, 1987; Huland et al., 1990).
We have previously shown that specific Escherichia coli
bacteria and lipopolysaccharides (LPS) are capable of
inducing shedding of normal urothelial cells (Aronson et
al., 1988). Shed cells originated from all the different mucosal
layers: the majority of these cells was found to be viable.
Desquamation starts about 1 h after LPS instillation, long
before the appearance of polymorphonuclear cells. In
addition, it was found that administration of aprotinin, an
inhibitor of proteolytic enzymes, considerably abrogated the
extent of shedding. These results suggest that the epithelial
cells secrete proteolytic enzymes whose activity results in
shedding, and that the cells are programmed to respond with
shedding following proper stimuli. Our working hypothesis
regards shedding as an antimicrobial defence mechanism,
since bacteria which adhere to shed epithelial cells are washed
out.
We have recently made use of the phenomenon of LPS-
induced shedding for early detection of experimentally
induced bladder tumour and, indeed, the efficacy of this
method is considerably higher than that obtainable by
irrigation of the bladder with saline (Nativ et al., 1994). In
the present study we investigated whether intravesical
administration of LPS may also serve as an effective
treatment for experimentally induced bladder tumour. This
study was carried out with two tumour variants, T5 and T50,
the latter being much more aggressively invasive than the
former. Variant T50 was obtained by successive subcutaneous
transplantations over a year, and could induce faster tumour
development in the bladder without resorting to cauterisation
- a procedure which was found to be indispensable for
obtaining successful tumour growth with T5.
The T5 variant was kept frozen to prevent changes owing
to serial transplantations, but it required five subcutaneous
transplantations before it could grow successfully and
develop in the bladder following transplantation.
Materials and methods
Animals
Inbred 8-10-week-old female C3H/eb mice obtained from
the animal facility of the Sackler School of Medicine, Tel
Aviv, Israel were used. Mice were housed at room
temperature of 22-24°C with 50-70% humidity and a
12 h- 12 h dark light cycle.
Tumour
FANFT-induced mouse bladder tumour (MBT-2) was kindly
provided by William R Fair of Memorial Sloan-Kettering
Cancer Center, New York. The tumour was initially
maintained by serial subcutaneous transplantations into the
back of C3H/eb mice; after five transplantations the T5
variant was obtained, whereas the T50 variant was obtained
after 50 transplantations.
Tumour cell implantation
Preparation of single cell suspensions from subcutaneous
tumours was done by mincing the fresh tumour under aseptic
conditions and adding RPMI-1640 medium to the minced
tissue. The suspension consisted of small cell aggregates,
which upon trypsinisation lost their ability to develop into
tumours in the bladder. On the other hand, trypsinisation (of
another aliquot) was used to determine the exact number of
cells injected. The number of viable cells was determined by
trypan blue exclusion. For implantation of tumour cells the
mice were anaesthetised with subcutaneous injection of
sodium pentobarbital (0.05 mg g-1 body weight). A 24-
gauge teflon IV catheter was inserted into the bladder
transurethrally. A guidewire was introduced into the lumen
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of the catheter which, with the use of an electrocautery unit,
could cause thermal injury to the bladder mucosa. A total of
105 viable tumour cells in 0.05-0.1 ml volume were delivered
to the bladder through the cannula. The mice remained
anaesthetised for another 45-60 min to prevent voiding of
tumour cells. It should be remarked that this procedure was
designed to float the cells in the bladder.
Studies with T5
The animals were divided into three groups. Group 1 (n=38)
was left untreated after tumour implantation. Group 2
(n=42) was subjected to 4-6 intravesical instillations of
200 Mg in 0.05-0.1 ml of active LPS (E. coli B4:055 Difco).
Treatment started either 3 or 7 days after the implantation
and was administered every other day. Group 3 (n=32) was
treated under the same regimen as group 2, but the material
injected consisted either of saline or of non-active LPS
(E. coli 0111B4 Difco).
All the treatments were carried out under light pento-
barbital anaesthesia, and the various agents were inserted
into the bladder via a 24-gauge teflon catheter.
Studies with T50
Two series of experiments were conducted, the conditions of
the first series being similar to those of the T5 experiments. It
was found, however, that if 3 days were allowed to elapse
between implantation of tumour cells and the beginning of
treatment, the tumour did not respond to the treatment. In
the second series, treatment was therefore started 1 or 2 days
after tumour implantation.
Statistical analysis
Comparison between treated subgroups was done by non-
parametric (Kruskal-Wallis) analysis of variance.
Results
Studies with T5
In the present study, a total of 149 female C3H/eb mice were
treated in five independent experiments. Upon completion of
the treatment regimen, the animals were sacrificed, the
bladders removed, weighed, processed for histology, stained
with haematoxylin and eosin and examined in blind fashion
by the study pathologists. Our findings, summarised in Table
I, are based solely on results obtained from the 112 animals
(75% of total) in which successful tumour implantation was
observed.
The mean bladder weight of untreated controls (group 1)
reached 206+131 mg, while bladders obtained from the
active LPS-treated animals had significantly lower weight
[79 +106 mg (P<0.0001)]. In the third group of animals,
Table I Effect of LPS on MBT-2 tumour weight in C3H/eb mice
following intravesical instillation
Tumour type and
initiation of Treatment group, mean bladder weight
treatment mg (±s.d.) P-valuea
Inactive
Untreated Active LPS LPS/saline
T5, regular 206 (+131) 79 (+106) 141 (+106) 0.0001
treatment (n =38) (n =42) (n =32)
T5, delayed 300 (+133) 253 (±149) 290 (+112) NS
treatment (n= 15) (n= 13) (n= 17)
T50, regular 278 (+125) 271 (+165) 273 (+143) NS
treatment (n= 13) (n= 15) (n=21)
T50, early 278 (+ 125) 63 (+62) 140 (±88) 0.0001
treatment (n= 13) (n= 12) (n=21)
aKruskal-Wallis ANOVA. NS, Not significant.
which were treated either with saline or with inactive LPS,
average bladder weight was 141 + 106 mg. While this is
significantly higher than the weight of animals treated with
active LPS (P<0.005), it is definitely lower than that of
untreated animals, although this difference is not significant.
The difference between the untreated animals and those
treated by inactive LPS or saline is attributed to cellular
desquamation owing to the mechanical effect of bladder
irrigation. Examination of the shed cells (following all the
treatment modalities) revealed that over 90% were oftumoral
origin. Beginning 6 h after administration of LPS, migration
of polymorphonuclear cells were observed, but without
subsequent appearance of macrophages. Inflammatory
processes were recorded at a rate of 2.5% - no difference
being noted between saline or active LPS-treated animals.
In a second cohort of animals, treatment was delayed up
to 7 days after tumour cells' implantation. No significant
differences in tumour size or weight were noted among the
three groups. Thus, the average bladder weights of untreated,
active endotoxin-treated and saline or inactive endotoxin-
treated animals were 300, 253 and 290 mg respectively. The
lack of response under these conditions seems to result from
the fact that by the 7th day after implantation the T5 tumour
cells have already deeply invaded the mucosa, and
consequently were not exposed to the action of LPS.
Studies with T50
When treatment was initiated according to the standard
procedure, 3 days after tumour implantation, administration
of endotoxin was not effective, (as shown in Table I) the
average weights of bladders of untreated, endotoxin-treated
and saline-treated animals being 278 +125, 271 + 165 and
273+ 143 mg respectively (results of five separate experiments
comprising 150 mice). The results resemble those obtained
with T5 upon delayed treatment (7 days). Hence, we studied
the effect of LPS administration 1 or 2 days after tumour
implantation. It was found that a considerable reduction of
tumour weight indeed resulted following LPS treatment
(P<0.0001), the figures being 278+125, 63+62 and
140+88 mg respectively (results of three separate experi-
ments including 100 mice).
Discussion
In the management of superficial bladder carcinoma,
intravesical chemotherapy and immunotherapy are well-
established procedures. As evidenced by several studies, the
various agents in use can reduce the rate of tumour
recurrence. Controlled clinical trials have shown that,
following chemotherapy, the rate of tumour recurrence is
reduced by 16-18%, immunotherapy achieved a complete
response in about half of the patients with papillary tumours
and over 70% in those with carcinoma in situ (Koontz et al.,
1981; Schulman et al., 1982; Garnick et al., 1984; Soloway et
al., 1981; Herr et al., 1989). Ofmore importance is the impact
of intravesical therapy on tumour progression and patient
survival in superficial bladder cancer. In a study comprising
over 1400 patients randomly treated intravesically by various
chemotherapeutic agents (thiotepa, mitomycin C or doxor-
ubicin), no significant difference was found by Lamm and
Griffith (1992) between the various treatment groups. In
various clinical studies on the efficacy of Bacillus Calmette-
Guerin (BCG), summarised in a recent publication (Kamat et
al., 1994), the response rate varied between 59 and 80%.
Clearly, more effective strategies are needed for the treatment
of superficial bladder cancer.
Our results show that intravesical instillation ofactive LPS
considerably reduces the rate of growth of implanted MBT-2
cells. LPS was injected repeatedly into the animals and no
side-effects were noted. We assume that the reduced pace of
tumour progression was caused by induction of shedding of
the tumour cells, according to evidence gained from ourTreatment of bladder tumour by UPS-induced shedding
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previous study on early detection of experimental bladder
tumour by means of LPS administration (Nativ et al., 1994).
In addition, histological examination of the resected bladder
revealed no indication for local immunological process.
However, in order for shedding to occur physical contact is
required between the injected material and the tumour cells.
The ineffectiveness in the late treatment of T5 is in agreement
with this notion. The T50 variant proved to be very
aggressive as it required no prior cauterisation of the
bladder in order to be implanted successfully and also in
this case we assume that there was not sufficient contact
between the injected LPS and the tumour cells even after 3
days as many ofthe latter have already invaded deeper layers
of the bladder.
The anti-tumour properties of LPS are well known, and
are generally attributed to systemic stimulation of the
immune system. In the present study, however, we are
dealing with a local effect, probably restricted to action on
the epithelial cells. Considering that LPS has been shown
(Ding et al., 1992) to interact with the microtubule network,
we may speculate that such a mechanism is involved in the
shedding phenomenon.
With the isolation of a non-toxic lipid A fraction
containing tumour regression activity (Takayama et al.,
1981), it will be of interest to test the latter's shedding
potential with a view to clinical application.
The experimental model currently used has its short-
comings: there is a large scatter of tumour progression rates
following implantation. A considerable effort was undertaken
to improve the reproducibility of our results which, however,
did not prove to be successful. Since the use of trypsinisation
for obtaining single cells was counterindicated we tried to
obtain the latter by gradient centrifugation or by selective
filtrations. However, the separated single cells seem to have a
tendency to aggregate and the extent of scatter in these
experiments was not diminished. The MBT-2 tumour
employed by us is most commonly used, and considered a
particularly suitable model for human bladder cancer; hence,
we did not study other tumour models. Our purpose was to
verify our assumption that induction of shedding will reduce
the tumour mass: that is, such a technique can serve as an
adjuvant to tumour resection.
Finally, by the use of LPS, earlier detection of the
presence of tumour cells becomes possible, thus increasing
the effectiveness of treatment by this agent.
References
ARONSON M, MEDALIA 0, AMICHAY D AND NATIV 0. (1988).
Endotoxin-induced shedding of viable uroepithelial cells is an
antimicrobial defence mechanism. Infect. Immun., 56, 1615-
1617.
DING A, SANCHEZ E, TANCINCO M AND NATHAN C. (1992).
Interactions of bacterial lipopolysaccharide with microtubule
proteins. J. Immunol., 148, 2853-2858.
GARNICK MB, SCHADEF D AND ISRAEL M. (1984). Intravesical
doxorubicin for prophylaxis in the management of recurrent
superficial bladder carcinoma. J. Urol., 131, 43-46.
HERR WH, LAUDONE VP AND WHITMORE WF Jr. (1987). An
overview ofintravesical therapy for superficial bladder tumors. J.
Urol., 138, 1363- 1368.
HERR WH, BADALAMENT RA, AMATO DA, LAUDONE VP, FAIR
WR AND WHITMORE WF Jr. (1989). Superficial bladder cancer
treated with Bacillus Calmette-Guerin: a multivariate analysis of
factors affecting tumor progression. J. Urol., 141, 22-28.
HULAND H, KLOPPEL G AND FEDDERSON I. (1990). Comparison
of different schedules of cytostatic intravesical instillations in
patients with superficial bladder carcinoma. Final evaluation of
prospective multicenter study with 419 patients. J. Urol., 144,
68-71.
KAMAT MR, KULKARNI JN, TONGAOKNAR HB AND DALAL AF.
(1994). Intravesical Bacillus Calmette-Guerin for superficial
bladder cancer: experience with Danish 1331 strain. J. Urol.,
152, 1424- 1428.
KOONTZ WW Jr, PROUT GR AND SMITH W. (1981). The use of
intravesical thiotepa in the management of noninvasive
carcinoma of the bladder. J. Urol., 125, 307-312.
LAMM DL AND GRIFFITH JE. (1992). Intravesical therapy: Does it
affect the natural history of superficial bladder cancer. Semin.
Urol., 10, 39-43.
NATIV 0, MEDALIA 0, ENGELBERG SI, RAVIV G AND ARONSON
M. (1994). Enhanced cytologic detection of early stage mouse
bladder tumor following induction ofuroepithelial cell shedding.
J. Urol., 152, 217-219.
RUBBEN H, LUTZEYER LW, FISCHER N, DEUTZ F, LA GRANGE I
AND GIANI G. (1988). Natural history and treatment oflow and
high risk superficial bladder tumors. J. Urol., 139, 283-285.
SCHULMAN CC, ROBINSON M AND DENIS L. (1982). Prophylactic
chemotherapy of superficial transitional cell bladder carcinoma:
an EORTC randomized trial comparing thiotepa, VM-26 and
TUR alone. Eur. Urol., 8, 207-212.
SILVERBERG E, BORING C AND SQUIRES T. (1990). Cancer
statistics- 1990. Ca-Cancer J. Clin., 40, 9-26.
SOLOWAY MS, MURPHY WM AND DEFUSIA MD. (1981). The effect
ofmitomycin C on superficial bladder cancer. J. Urol., 125, 646-
648.
SOLOWAY MS. (1987). Selecting initial therapy for bladder cancer.
Cancer, 60, 502-513.
TAKAYAMA K, RIBI E AND CANTRELL JL. (1981). Isolation of a
nontoxic lipid A fraction containing tumor regression activity.
Cancer Res., 41, 2654-2657.
TORTI FM AND LUM BI. (1984). The biology and treatment of
superficial bladder cancer. J. Clin. Oncol., 2, 505-551.